Absci (ABSI) will host a virtual seminar on December 11, 2025 at 10:00am ET focused on the company’s ABS-201 program for androgenetic alopecia. Additionally, Absci now expects to initiate the Phase 1/2a trial for this program in early December, ahead of prior guidance for early 2026, with an interim efficacy readout anticipated in the second half of 2026. The seminar to be hosted on December 11 will feature leading KOLs in the dermatology and hair loss fields, and highlight the clinical trial path, differentiated profile, and market potential of the ABS-201 program.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABSI:
- Absci participates in a conference call with JPMorgan
- Promising Prospects for AbSci’s ABS-101: A Buy Rating Backed by Strong Pharmacology and Partnership Potential
- Video: Credit bureaus sink after FICO bring Scores directly to customers
- Morning Movers: Occidental higher after $9.7B sale of OxyChem to Berkshire
- Absci initiated with an Overweight at JPMorgan